NPCE Stock Analysis: Buy, Sell, or Hold?
NPCE - Neuropace, Inc. Common Stock
$15.13
-0.19 (-1.24%)
▼
5d:
-9.46%
30d:
-2.2%
90d:
+49.36%
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Mar 03, 2026
28d
Get Alerted When NPCE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NPCE shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: NPCE shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: NPCE is currently trading at $15.13, which is considered oversold relative to its 30-day fair value range of $15.60 to $16.89.
Technical Outlook: Technically, NPCE is in a strong uptrend. The price is currently testing key support at $14.88. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $19.38 (+28.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NPCE is in a strong uptrend. The price is currently testing key support at $14.88. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $19.38 (+28.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$15.60 -
$16.89
Company Quality Score
51/100
(HOLD)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 28.1% below Wall St target ($19.38)
- CAUTION: Recommendation downgraded due to -9.5% 5-day decline
Fair Price Analysis
30-Day Fair Range
$15.60 -
$16.89
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$1.98
(13.1%)
Support & Resistance Levels
Support Level
$14.88
Resistance Level
$17.55
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-21.01
Wall Street Target
$19.38
(+28.1%)
Revenue Growth (YoY)
29.9%
Profit Margin
-25.3%
Last updated: February 01, 2026 11:02 PM ET
Data refreshes hourly during market hours. Next update: 12:02 AM
Data refreshes hourly during market hours. Next update: 12:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NPCE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 68 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$85 | 65 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$134 | 63 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 63 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 59 HOLD |
